Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ketamine Hydrochloride Clear all
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

NCT01100255
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine infusion, Saline
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 19, 2026, 8:55 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Imaging Depression in Parkinson's Disease

NCT06402955
View directory record Official record
Conditions
Parkinson's Disease, Major Depressive Disorder
Interventions
11C-UCB-J, ketamine hydrochloride
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

NCT03621085
View directory record Official record
Conditions
Hemorrhage, Healthy
Interventions
Ketamine Hydrochloride, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD

NCT06036511
View directory record Official record
Conditions
PTSD
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 19, 2026, 8:55 PM EDT
Active, not recruiting Phase 3 Interventional

Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain

NCT02866071
View directory record Official record
Conditions
Acute Traumatic Pain
Interventions
Ketamine Hydrochloride, Placebo-Comparator
Drug
Lead sponsor
Jason McMullan
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
ketamine, midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 19, 2026, 8:55 PM EDT
Completed No phase listed Observational

Exploring Sedation Types During Cataract Surgery

NCT04725747
View directory record Official record
Conditions
Vital Signs
Interventions
Midazolam/Ketamine HCl 3mg-50mg sublingual, Intravenous Sedatives with or Without Analgesia
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
55 Years to 80 Years
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 19, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 19, 2026, 8:55 PM EDT
Terminated Early Phase 1 Interventional

Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study

NCT03067974
View directory record Official record
Conditions
Failed Moderate Sedation During Procedure, Ketamine Adverse Reaction
Interventions
Ketamine Hcl 100Mg/Ml Inj
Drug
Lead sponsor
University of Arizona
Other
Eligibility
2 Years to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

NCT04714541
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Ketamine Hcl 50Mg/Ml Inj
Drug
Lead sponsor
Homeostasis Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Windsor, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 19, 2026, 8:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Pregnancy Registry for Psychiatric Medications

NCT01246765
View directory record Official record
Conditions
Pregnant Women, Psychotropic Drugs
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

NCT00662883
View directory record Official record
Conditions
Healthy
Interventions
PMI-150 (intranasal ketamine HCl); mometasone furoate
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients

NCT02935595
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 19, 2026, 8:55 PM EDT
Terminated Early Phase 1 Interventional

Ketamine in Veterans With Gulf War Illness

NCT04712071
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 19, 2026, 8:55 PM EDT
Terminated Phase 3 Interventional Results available

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

NCT04260607
View directory record Official record
Conditions
Suicide, Suicide Threat, Depression Severe
Interventions
Ketamine Hydrochloride, Normal saline
Drug
Lead sponsor
Naval Medical Center Camp Lejeune
Federal
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Marine Corps Base Camp Lejeune, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain

NCT05864053
View directory record Official record
Conditions
Pain, Neuropathic
Interventions
Ketamine, (2R,6R)-hydroxynorketamine, Saline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 19, 2026, 8:55 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neurobiology of Suicide

NCT02543983
View directory record Official record
Conditions
Healthy Volunteers, Depression
Interventions
Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride
Device · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 19, 2026, 8:55 PM EDT